Accenture Federal Services Awarded a Position on National Cancer Institute’s IT Services Blanket Purchase Agreement

Rhea-AI Summary

Accenture Federal Services (AFS), a subsidiary of Accenture (NYSE: ACN), secured a position on a $137 million Blanket Purchase Agreement (BPA) with the National Cancer Institute (NCI) for software engineering and IT support services. The agreement spans five years, focusing on enhancing technology trends and supporting NCI’s mission-critical cancer research and scientific initiatives. This partnership aims to deliver software and support to various NCI applications, helping promote health and longevity through advanced technology adoption.

Positive

• Secured a $137 million Blanket Purchase Agreement with NCI over five years.
• Will enhance NCI's technological capabilities for cancer research.

Negative

• None.

ARLINGTON, Va.--(BUSINESS WIRE)-- Accenture Federal Services (AFS), a subsidiary of Accenture (NYSE: ACN), has been awarded a position on a software engineering and IT support services Blanket Purchase Agreement (BPA) with the National Cancer Institute (NCI) Information Technology (IT) Engineering office.

Accenture Federal Services Managing Director and Federal Health Leader, Jill Olmstead (Photo: Business Wire)

Specifically, the company will deliver a variety of software engineering and support services to NCI customers and the Institute’s scientific, grants management, and business applications.

“Accenture Federal Services looks forward to enhancing the National Cancer Institute’s ability to keep pace with technology trends, adopt emerging technologies, and help move innovative ideas to solution delivery and production,” said Accenture Federal Services Managing Director and Federal Health Leader, Jill Olmstead. “We’re thrilled to support the National Cancer Institute with its mission-critical work conducting cancer research and advancing scientific knowledge to help people live longer, healthier lives.”

The BPA is valued at $137 million over a period of five years.

NCI is one of 27 institutes and centers that comprise the National Institutes of Health (NIH).

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Technology and Operations services and Accenture Song — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 721,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners, and communities. Visit us at accenture.com.

About Accenture Federal Services

Accenture Federal Services, a wholly owned subsidiary of Accenture LLP, is a U.S. company headquartered in Arlington, Virginia. We serve every Cabinet-level department and 30 of the largest federal organizations. Accenture Federal Services transforms bold ideas into breakthrough outcomes for clients at defense, national security, public safety, civilian and military health organizations. Visit us at accenturefederal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005050/en/

Donna Savarese

Accenture

+1 301 250 0660

donna.savarese@accenturefederal.com

Source: Accenture

FAQ

What is the value and duration of Accenture's BPA with NCI?

The Blanket Purchase Agreement is valued at $137 million over a period of five years.

What services will Accenture provide under the BPA with NCI?

Accenture will deliver software engineering and IT support services to NCI's scientific, grants management, and business applications.

Which subsidiary of Accenture is involved in the BPA with NCI?

Accenture Federal Services is the subsidiary involved in this Blanket Purchase Agreement.

What is the main goal of the partnership between Accenture and NCI?

The partnership aims to enhance NCI's ability to keep pace with technology trends and support its cancer research initiatives.